You can start thinking about how to fool it or block it
For more than a century, tuberculosis has endured as one of humanity's most persistent killers, surviving not through brute force alone but through an almost elegant capacity for self-preservation. Researchers at the University of Guelph have now illuminated a hidden mechanism at the heart of that survival — a molecular sorting gate that helps the bacterium manage stress inside the very immune cells meant to destroy it. By mapping, at near-atomic resolution, how this protein recognizes and routes cellular damage, the team has opened a door that drug designers have long sought: a way to cripple the pathogen's resilience rather than simply attempt to kill it outright.
- Tuberculosis claims over a million lives each year, and growing resistance to existing antibiotics is steadily narrowing the already limited arsenal available to treat it.
- The bacterium's secret weapon is a protein-recycling system that lets it manage the stress of surviving inside immune cells — and until now, the precise mechanics of its sorting gate, Bpa, remained unmapped and undruggable.
- PhD candidate Bradley Davis engineered a workaround to isolate Bpa's elusive targets, using nuclear magnetic resonance spectroscopy to reveal, at near-atomic detail, how the protein shape-shifts under stress to become a more efficient cleanup machine.
- The discovery that Bpa hunts for exposed 'greasy' patches on damaged proteins gives drug designers a concrete handle — block that recognition, and the bacterium loses its ability to cope with immune attack.
- A new class of antibiotics targeting Bpa could potentially shorten the grueling six-to-twelve-month treatment regimen and offer a viable path against drug-resistant strains, though the translational work lies ahead.
Tuberculosis persists as one of the world's deadliest infectious diseases not merely because of its virulence, but because of its cunning. The bacterium has evolved to survive inside the immune cells designed to destroy it, managing cellular stress with quiet efficiency. As resistance erodes the power of conventional antibiotics, researchers at the University of Guelph have turned their attention to the pathogen's own survival machinery — and found a promising point of attack.
Dr. Siavash Vahidi's team focused on a protein called Bpa, which serves as the sorting gate for the TB bacterium's proteasome — a recycling center that breaks down damaged proteins before they accumulate and destabilize the cell. Under assault from the immune system, this cleanup operation is critical to the bacterium's survival. Yet what Bpa actually recognizes when selecting proteins for destruction had remained an open question, making it nearly impossible to design drugs that could interfere with it.
Lead author Bradley Davis, a PhD candidate, solved the isolation problem by engineering a model target from a fragment of human protein, then used nuclear magnetic resonance spectroscopy to map the interaction at near-atomic resolution. What emerged was a vivid picture: under the warm, hostile conditions inside immune cells, Bpa assembles from inactive units into a ring-shaped structure far more capable of capturing damaged proteins. The bacterium, in effect, shape-shifts under pressure. Bpa does this by detecting exposed hydrophobic — or 'greasy' — patches that appear on proteins when they are stressed or damaged, regions normally hidden inside healthy molecules.
The significance lies in what this mechanistic clarity makes possible. Rather than killing the bacterium directly, future drugs could trap Bpa in its inactive state, stripping TB of its ability to manage immune-cell stress and leaving it exposed to the body's natural defenses. Such an approach could offer an alternative to the current six-to-twelve-month antibiotic regimens and provide traction against drug-resistant strains where conventional treatments are failing.
The research was a cross-institutional collaboration involving Dr. Lewis Kay's lab at the University of Toronto and scientists at Waters Corporation, whose mass spectrometry equipment proved essential. Published in Nature Communications, the work represents a conceptual shift in how the field might approach tuberculosis — not by overwhelming the enemy, but by dismantling its capacity to endure.
Tuberculosis kills more than a million people every year, making it one of the world's most lethal infectious diseases. What makes the bacterium so hard to eliminate is not just its virulence but its cunning—it has learned to survive inside the very immune cells designed to destroy it, and it does this by managing stress with remarkable efficiency. As antibiotics that target DNA replication and protein synthesis lose their power against resistant strains, researchers are turning their attention to the bacterium's own survival machinery, looking for ways to sabotage it from within.
At the University of Guelph, a team led by Dr. Siavash Vahidi has mapped the inner workings of a protein called Bacterial proteasome activator, or Bpa, which acts as the sorting gate in the TB bacterium's recycling center. This recycling center, called the proteasome, breaks down damaged proteins before they can pile up and cripple the cell. For a bacterium under constant assault from the immune system, this cleanup operation is essential to survival. Yet until now, researchers have been stuck on a fundamental question: What exactly does Bpa recognize when it selects a protein for destruction? Without that answer, designing drugs to interfere with it seemed impossible.
The problem was that Bpa's natural targets are unstable and difficult to isolate in the laboratory. Bradley Davis, a PhD candidate and the study's lead author, found a workaround. He engineered a model target using a piece of human protein, then used specialized nuclear magnetic resonance spectroscopy to map, at near-atomic resolution, how Bpa recognizes its targets and transforms itself in response to stress. The picture that emerged was striking: under the warm, hostile conditions inside immune cells, the Bpa complex assembles from smaller, inactive units into a ring-shaped structure far better equipped to grab proteins and send them to the proteasome for destruction. The bacterium, in other words, shape-shifts under pressure.
Bpa recognizes target proteins by identifying exposed "greasy" patches—hydrophobic regions that are normally buried inside healthy proteins but become exposed when proteins are damaged or stressed. Once researchers understood what Bpa was looking for, the path forward became clearer. "You can start thinking about how to fool it or block it," Davis explained. This kind of mechanistic detail is exactly what drug designers need to begin their work.
The implications are significant. Current tuberculosis treatment requires six to 12 months of antibiotics, a grueling regimen made worse by the bacterium's growing resistance to the limited drugs available. Vahidi envisions a different kind of antibiotic—one that does not kill the bacterium outright but instead disables its stress-response machinery. If future drugs could trap Bpa in an inactive state, the bacterium would lose its ability to manage the stress of living inside immune cells, leaving it vulnerable to the body's natural defenses. "This is the long game," Vahidi said, but the stakes are clear: if researchers can interrupt how the TB proteasome decides what to destroy, they can interfere with the bacterium's ability to cope with immune attack—exactly where drug-resistant strains are most vulnerable.
The work was a collaboration spanning the Vahidi lab at Guelph, Dr. Lewis Kay's lab at the University of Toronto, and scientists at Waters Corporation, who provided access to advanced mass spectrometry equipment. Vahidi emphasized that the breakthrough required pulling together techniques that rarely appear in the same study, and that the collaborators made it possible to ask questions that no single lab could have pursued alone. The research, published in Nature Communications, represents a shift in how the field thinks about fighting tuberculosis—not by killing the enemy, but by crippling its ability to survive.
Notable Quotes
Without that answer, you cannot really design molecules to interfere with it.— Dr. Siavash Vahidi, on understanding what Bpa recognizes
If we can interrupt how the TB proteasome chooses what to destroy, we can interfere with how the bacterium copes with the immune system. That's exactly where drug-resistant strains are at their most vulnerable.— Dr. Siavash Vahidi, on the therapeutic potential
The Hearth Conversation Another angle on the story
Why has Bpa been so hard to study until now?
The proteins that Bpa targets are naturally unstable and fall apart quickly outside the cell. Researchers couldn't isolate them long enough to observe how Bpa interacts with them. Davis solved this by building a synthetic target that was stable enough to work with in the lab.
So the bacterium is essentially shape-shifting to survive. How does that help it?
Exactly. Inside an immune cell, conditions are harsh—warm, acidic, full of enzymes trying to break things down. When Bpa senses that stress, it assembles into a more active form, like a machine switching into high gear. It becomes much better at clearing away damaged proteins before they accumulate and poison the cell.
And if you could keep Bpa stuck in its inactive form?
The bacterium would lose that ability to clean up after itself. Damaged proteins would pile up, cellular processes would fail, and the immune system would have an easier time killing it. You're not poisoning the bacterium directly—you're making it unable to cope with the stress it's already under.
Why does this matter more now than it would have ten years ago?
Antibiotic resistance. The drugs we've relied on for decades are losing effectiveness. We need new approaches, new targets. Bpa is attractive because it's essential for survival in the human body, but it's not a target the bacterium has had to evolve defenses against yet.
How long before this becomes a drug?
That's the honest answer: years. Maybe many years. But they've answered the foundational question—what does Bpa actually see when it picks a target? Everything else builds from there.